Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia

被引：25
作者：
Liersch, Ruediger [1 ]
Schliemann, Christoph [1 ]
Bieker, Ralf [1 ]
Hintelmann, Heike [1 ]
Buechner, Thomas [1 ]
Berdel, Wolfgang E. [1 ]
Mesters, Rolf M. [1 ]
机构：
[1] Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany
来源：
LEUKEMIA RESEARCH | 2008年 / 32卷 / 06期
关键词：
VEGF-C; VEGFR-3; acute myeloid leukaemia; angiogenesis; prognosis;
D O I：
10.1016/j.leukres.2007.10.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vascular endothelial growth factor-C (VEGF-C) has been shown to promote survival and resistance to chemotherapy of AML-cells in vitro. We investigated the expression of VEGF-C/VEGFR-3 in the bone marrow and pretherapeutic plasma levels of VEGF-C in patients with newly diagnosed AML. Expression of VEGF-C/VEGFR-3 was significantly higher in AML patients than in controls, while circulating levels did not differ. However, VEGF-C/VEGFR-3 expression was not able to predict clinical outcome. In conclusion, AML is associated with an increased expression of VEGF-C/VEGFR-3. Although expression levels display no prognostic significance in our study, strategies targeting the VEGF-C/VEGFR-3-pathway might be a promising treatment approach. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：954 / 961
页数：8
相关论文
共 36 条
  • [1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    Aguayo, A
    Kantarjian, H
    Manshouri, T
    Gidel, C
    Estey, E
    Thomas, D
    Koller, C
    Estrov, Z
    O'Brien, S
    Keating, M
    Freireich, E
    Albitar, M
    [J]. BLOOD, 2000, 96 (06) : 2240 - 2245
  • [2] Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
    Aguayo, A
    Estey, E
    Kantarjian, H
    Mansouri, T
    Gidel, C
    Keating, M
    Giles, F
    Estrov, Z
    Barlogie, B
    Albitar, M
    [J]. BLOOD, 1999, 94 (11) : 3717 - 3721
  • [3] Bellamy WT, 1999, CANCER RES, V59, P728
  • [4] Bieker R, 2003, CANCER RES, V63, P7241
  • [5] Vascular endothelial growth factor C induces angiogenesis in vivo
    Cao, YH
    Linden, P
    Farnebo, J
    Cao, RH
    Eriksson, A
    Kumar, V
    Qi, JH
    Claesson-Welsh, L
    Alitalo, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) : 14389 - 14394
  • [6] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [7] Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
    Dias, S
    Choy, M
    Alitalo, K
    Rafii, S
    [J]. BLOOD, 2002, 99 (06) : 2179 - 2184
  • [8] Duff SE, 2003, INT J ONCOL, V22, P339
  • [9] Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
    Faderl, S
    Do, KA
    Johnson, MM
    Keating, M
    O'Brien, S
    Jilani, I
    Ferrajoli, A
    Ravandi-Kashani, F
    Aguilar, C
    Dey, A
    Thomas, DA
    Giles, FJ
    Kantarjian, HM
    Albitar, M
    [J]. BLOOD, 2005, 106 (13) : 4303 - 4307
  • [10] A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
    Fiedler, W
    Mesters, R
    Tinnefeld, H
    Loges, S
    Staib, P
    Dührsen, U
    Flasshove, M
    Ottmann, OG
    Jung, WF
    Cavalli, F
    Kuse, R
    Thomalla, J
    Serve, H
    O'Farrell, AM
    Jacobs, M
    Brega, NM
    Scigalla, P
    Hossfeld, DK
    Berdel, WE
    [J]. BLOOD, 2003, 102 (08) : 2763 - 2767
1234